These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 8171728)
1. Evaluation of commercially available antacid tablets. Nain CK; Singh K; Verma M; Vinayak VK; Ganguly NK Trop Gastroenterol; 1993; 14(4):139-43. PubMed ID: 8171728 [TBL] [Abstract][Full Text] [Related]
2. The neutralizing capacity and sodium content of antacid brands on the Kenyan market. Kibwage IO; Machine A; Hagos B; Hoogmartens J East Afr Med J; 1995 Mar; 72(3):194-7. PubMed ID: 7796775 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of antacid gel preparations available commercially in the Indian market. Nain CK; Singh K; Dhawan V; Vinayak VK; Ganguly NK Trop Gastroenterol; 1992; 13(2):70-4. PubMed ID: 1413102 [TBL] [Abstract][Full Text] [Related]
4. A comparative study of the neutralising capacity of eight brands of antacids. Hagos B; Nganga JN; Juma FD; Ndegwa P East Afr Med J; 1989 Jun; 66(6):408-10. PubMed ID: 2791947 [TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of liquid antacid products. Sherrill MC; Rudd GD Am J Hosp Pharm; 1982 Feb; 39(2):300-2. PubMed ID: 7058802 [TBL] [Abstract][Full Text] [Related]
6. Invitro evaluation of the neutralising capacity of twenty brands of antacids in Lagos, Nigeria. Adepoju-Bello AA; Akpabio UE; Ayoola GA; Coker HA; Enwuru NV Nig Q J Hosp Med; 2008; 18(3):153-5. PubMed ID: 19062480 [TBL] [Abstract][Full Text] [Related]
7. In vitro buffering capacities of proprietary non-particulate antacids available in New Zealand. Watts DW Anaesth Intensive Care; 1994 Apr; 22(2):184-6. PubMed ID: 8210023 [TBL] [Abstract][Full Text] [Related]
8. Why do apparently healthy people use antacid tablets? Graham DY; Smith JL; Patterson DJ Am J Gastroenterol; 1983 May; 78(5):257-60. PubMed ID: 6846300 [TBL] [Abstract][Full Text] [Related]
9. In vitro comparison of the antacid potencies of almagate in tablets and suspension with those of other commercially available antacid preparations. Prieto R; Martinez-Tobed A; Fábregas JL; Beneyto JE Arzneimittelforschung; 1984; 34(10A):1360-4. PubMed ID: 6548920 [TBL] [Abstract][Full Text] [Related]
10. Neutralizing capacity and cost effectiveness of antacids. Drake D; Hollander D Ann Intern Med; 1981 Feb; 94(2):215-7. PubMed ID: 6781389 [TBL] [Abstract][Full Text] [Related]
12. Formulation of intelligent tablets with an antacid effect. Bajdik J; Korbely A; Pintye-Hódi K Pharm Dev Technol; 2009; 14(5):471-5. PubMed ID: 19552554 [TBL] [Abstract][Full Text] [Related]
13. [In vitro determination of the neutralizing capacity of antacids]. Brunner H Z Gastroenterol; 1983 Mar; 21 Suppl():22-5. PubMed ID: 6858407 [TBL] [Abstract][Full Text] [Related]
14. [Antacids: A comparison of their in vitro neutralizing capacity in hydrochloric acid and in acidified peptone solution (author's transl)]. Walther C; Herzog P; Hissnauer KH; Kühl HJ; Holtermüller KH Z Gastroenterol; 1982 May; 20(5):263-72. PubMed ID: 7102017 [TBL] [Abstract][Full Text] [Related]
15. Users and utilization patterns of over-the-counter acid inhibitors and antacids in The Netherlands. Van Vliet EP; Kuipers EJ; Steyerberg EW; Siersema PD Scand J Gastroenterol; 2008; 43(6):662-8. PubMed ID: 18569982 [TBL] [Abstract][Full Text] [Related]
16. In vitro evaluation of magaldrate antacid efficacy in the presence of some drugs and its effect on their dissolution rates: Part I. al Gohary OM Boll Chim Farm; 1996 Dec; 135(11):621-37. PubMed ID: 9066172 [TBL] [Abstract][Full Text] [Related]
17. [Evaluation of antacids "in vitro"]. Alvarez de Saldaña S; de Ramírez AF; Ramírez Mata M Rev Gastroenterol Mex; 1978; 43(3):127-30. PubMed ID: 33434 [TBL] [Abstract][Full Text] [Related]